Neulasta Market Size, Share & Trends Analysis Report By Drug Type (Branded, Biosimilars), Market Share (Branded, Biosimilars), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Route of Administration (Pre-filled Syringes, On-body Injectors (OBI)), By End User (Cancer Treatment Centers, Hospitals, Homecare Settings) and By Region (North America, Europe, Asia-Pacific, Latin America, The Middle East and Africa) Forecasts, 2025-2030

Neulasta Market Growth Factors

Rising Global Cancer Prevalence

The global burden of cancer continues to grow at an alarming rate, with over 29 million new cases projected by 2030, according to international health data. This rise is directly driving the demand for supportive care treatments like Neulasta (pegfilgrastim), which play a critical role in reducing chemotherapy-induced neutropenia a potentially life-threatening condition. In high-risk cancers such as breast, lung, and lymphomas, Neulasta is routinely prescribed as part of prophylactic treatment to maintain immune function during cytotoxic therapy. In parallel, emerging economies across Latin America, Asia, and the Middle East are rapidly scaling up their chemotherapy capabilities, as cancer care infrastructure improves and access to systemic therapies expands. This has significantly raised the clinical demand for neutropenia prevention and boosted adoption of drugs like Neulasta.

Public and Private Investment in Cancer Care Systems

Another major driver of the Neulasta market is the accelerated entry and acceptance of biosimilars such as Fulphila, Ziextenzo, and Nyvepria, which have made pegfilgrastim-based therapies more cost-accessible in both developed and developing markets. These biosimilars have received regulatory approval in numerous countries, making it possible for healthcare systems to expand neutropenia treatment coverage at a lower cost. Simultaneously, governments in India, China, and Brazil are investing heavily in cancer care infrastructure, including public oncology centers, diagnostic expansion, and subsidized treatment programs. These structural investments are increasing access to chemotherapy and, by extension, the supportive care drugs that go along with it. The combined effect of biosimilar affordability and health policy-driven expansion is creating a favorable environment for consistent Neulasta market growth through 2030.

Market Restraint

Barriers to Market Accessibility and Shifting Treatment Paradigms

The Neulasta market faces notable restraints that could hinder its long-term growth trajectory, particularly in price-sensitive and regulatory-challenged regions. The high cost of branded Neulasta limits its adoption in developing countries, where healthcare budgets are constrained and patients often pay out-of-pocket. While biosimilars offer a more affordable alternative, regulatory complexity with diverse approval standards across the U.S., EU, Asia, and Latin America delays their market entry and limits rapid accessibility. Furthermore, the increasing shift toward targeted therapies and immunotherapies in oncology is gradually reducing reliance on traditional chemotherapy regimens, which in turn diminishes the clinical need for supportive care drugs like Neulasta in specific cancer subtypes.

Market Opportunity

Expanding Access Through Innovation and Strategic Partnerships

The Neulasta market presents significant opportunities driven by technological innovation and strategic expansion initiatives. One of the most promising developments is the increasing adoption of home injection kits and On-Body Injectors (OBIs) such as Neulasta Onpro, which allow patients to self-administer the drug without visiting a healthcare facility. This enhances treatment adherence, improves patient convenience, and creates a strong value proposition for healthcare providers. Simultaneously, strategic collaborations between biosimilar manufacturers and regional distributors in Africa, Asia, and Eastern Europe are helping overcome market entry barriers and boost access in underserved areas. Additionally, the integration of digital health tools, including remote neutrophil monitoring and injection adherence apps, is improving real-time treatment tracking and care coordination offering a competitive edge to companies that embrace digital transformation.

Market Trend

Competitive Realignment and Evolving Clinical Practices

The Neulasta market is being reshaped by a combination of intensifying competition and evolving treatment strategies. A key trend is the onset of biosimilar pricing wars, where manufacturers are deploying aggressive discounting strategies to win hospital tenders and insurance contracts significantly influencing drug selection and reducing overall treatment costs. Concurrently, the oncology field is moving toward personalized care, with physicians increasingly using neutropenia risk profiling to tailor supportive therapies, making prescribing more targeted and outcome-driven. The impending patent expirations and ongoing regulatory approvals of new pegfilgrastim biosimilars beyond 2025 are expected to further fragment the market and diminish the market share of branded Neulasta, accelerating the shift toward value-based purchasing.

Drug Type Insights

The drug type segmentation of the Neulasta market is primarily divided between branded Neulasta and biosimilars such as Fulphila, Ziextenzo, and Nyvepria. In 2025, branded Neulasta holds approximately 56% of the market share, valued at USD 2.3 billion, driven by its established reputation and clinical trust. However, biosimilars, representing 44% of the market at USD 1.8 billion, are rapidly gaining traction due to their lower cost and expanding regulatory approvals. By 2030, biosimilars are expected to capture about 60% of the market share, reflecting growing cost sensitivity and increased biosimilar adoption worldwide.

Distribution Channels Insights

In terms of distribution channels, hospital pharmacies dominate due to their role in bulk purchasing for oncology treatments and widespread insurance coverage. Retail pharmacies are gaining importance, especially in regions like the U.S. and Europe, where home administration kits and on-body injectors (OBIs) enable patients to receive treatment outside hospital settings. Online pharmacies are expanding rapidly in the Asia Pacific and Latin America, leveraging increasing digital health adoption and e-commerce penetration, which helps improve accessibility in remote and underserved areas.

Route of Administration Insights

When segmented by route of administration, pre-filled syringes remain the most common delivery method, accounting for around 70% of market use in 2025. However, OBIs are gaining popularity because they allow patients to self-administer pegfilgrastim conveniently at home, aligning with the trend toward outpatient care. The share of OBIs is projected to increase from 30% in 2025 to 42% by 2030, driven by patient preference for ease of use, healthcare system support for homecare, and innovations in wearable drug delivery technologies.

End User Insights

The end-user segmentation highlights that cancer treatment centers and hospitals are the primary purchasers and administrators of Neulasta, reflecting their central role in chemotherapy management. However, homecare settings are emerging rapidly due to advances in self-administration technology and growing acceptance of home-based supportive care. The share of homecare administration is expected to rise significantly from around 18% in 2025 to 30% by 2030, supported by digital health tools and shifting healthcare policies favoring outpatient care to improve patient convenience and reduce costs.

Regional Analysis

North America commands the largest share of the Neulasta market with an estimated size of USD 1.9 billion in 2025, growing at a moderate CAGR of 3.6% through 2030. This growth is fueled by strong biosimilar uptake supported by favorable Medicare reimbursement policies and wide access to innovative delivery systems like the Neulasta Onpro on-body injector. Leading companies such as Amgen, Pfizer, and Mylan actively compete in this mature market, focusing on expanding biosimilar portfolios and improving patient adherence to maintain their market positions.

Europe Market Trends

Europe’s Neulasta market is valued at approximately USD 1.2 billion in 2025 and is expected to grow at a faster CAGR of 5.0%. This growth is largely driven by national biosimilar adoption policies and centralized drug procurement systems across countries, which promote cost-effective treatment options. However, pricing pressures and reimbursement delays remain significant challenges that impact market penetration and timing, requiring manufacturers to navigate complex regulatory environments and adapt pricing strategies accordingly.

In the Asia Pacific region, the market is forecasted at USD 600 million in 2025 with the highest CAGR of 7.2% through 2030, reflecting robust growth potential. Key opportunities include the rising cancer burden in populous countries such as India and China, alongside increasing acceptance of biosimilars in both public and private sectors. Nonetheless, regulatory complexity and limited oncology reimbursement in rural and underserved areas pose hurdles, necessitating targeted approaches to improve access and affordability.

The Latin America Neulasta market is valued at around USD 250 million in 2025, with a CAGR of 5.6%, driven by government-led cancer screening initiatives and growing hospital-based procurement of biosimilars. Despite these favorable factors, the region faces challenges including political and economic instability, which can disrupt supply chains and delay market expansion. Manufacturers aiming for growth must therefore factor in regional volatility and tailor their strategies for sustained engagement.

Finally, the Middle East & Africa market, estimated at USD 150 million in 2025 and growing at a CAGR of 6.3%, benefits from increasing investments in cancer care infrastructure in countries like the UAE, South Africa, and Saudi Arabia. However, the region struggles with limited oncology infrastructure and affordability constraints that restrict widespread access. Efforts to enhance healthcare capacity and implement supportive reimbursement policies will be critical to unlocking the full market potential in these emerging markets.

List of Key Players in Neulasta Market

1. Mylan/Biocon
2. Sandoz
3. Pfizer
4. Teva
5. Apotex
6. Accord
7. Fresenius Kabi

Recent Developments

• 2023: Pfizer's Nyvepria expands into European markets with aggressive pricing

• 2024: Amgen launches enhanced Neulasta Onpro injector with digital adherence monitoring

• 2024: Teva's biosimilar enters Latin American markets via strategic local partnerships

• 2025: FDA approval granted for a new pegfilgrastim biosimilar from a Korean biotech firm
  These developments are reshaping competitive dynamics and expanding access globally.